Tradestie Institutional Equity Comparison Engine

BHVN vs DNLI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BHVN Overall Edge

BHVN Captures Institutional Edge (3โ€“0 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BHVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DNLI at N/M Forward P/E and -2481.1% operating margin (-100.0% YoY). In options structure, BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against DNLI sits in BREAKDOWN (27th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BHVN N/M vs DNLI N/M Fwd P/E
Growth & Margin Winner BHVN
Op Margin 0.0% vs -2481.1% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner BHVN
1Y +72.1% vs +6.9% ยท 52W Pos 59% vs 25%
Options & Structure Winner BHVN
CONSOLIDATION (18th %ile IV) vs BREAKDOWN (27th %ile IV)
BHVN NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap $2.1B
1M Return +28.99%
1Y Return +72.09%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
DNLI NASDAQ
Denali Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.33
-2.19% 1D
Market Cap $3.0B
1M Return +4.09%
1Y Return +6.88%
Forward P/E N/M
Unified AI Score
55.5 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 66.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BHVN +72.09% DNLI +6.88% Spread: +65.21 pp (BHVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BHVN TTM Op. Margin: 0.0% DNLI TTM Op. Margin: -2481.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs DNLI. Trailing 12-month operating profitability (BHVN 0.0% vs DNLI -2481.1%) and valuation multiples (BHVN N/M vs DNLI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BHVN (3) vs DNLI (4)
Institutional Metric BHVN DNLI Criterion Row Winner
Market Capitalization Scale $2.1B $3.0B Larger Scale DNLI
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth BHVN
Operating Margin (TTM) Profitability 0.0% -2481.1% Higher Margin BHVN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -799.5% -33.9% Higher ROE DNLI
52-Week Range Position Momentum 59% ($8โ€“$18) 25% ($15โ€“$27) Stronger Trend BHVN
Beta / 30D Volatility Risk Regime 1.41ฮฒ ยท 111% Vol 1.36ฮฒ ยท 48% Vol Lower Realized Risk DNLI
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 55.5 / 100 (HOLD) Higher Composite DNLI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BHVN vs DNLI Buy Guide
BHVN CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live BHVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DNLI BREAKDOWN
91d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 27th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DNLI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BHVN nor DNLI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.